There is a version of this conversation where the EU access problem is a sequencing problem. You prioritise markets with favourable reimbursement environments, manage the low-anchor markets carefully, and run your access strategy as a series of country-level negotiations with a coordinating layer above them. That version still exists in most access planning decks. It is no longer an accurate description of the environment.
The EU access playbook that most organisations are operating from was designed for a world of independent national HTA systems, country-by-country negotiation, and a US commercial strategy that had no formal linkage to European pricing outcomes. That world ended. The transition was gradual enough that the break is not yet visible in most organisations' planning assumptions — but it is visible in the outcomes. Delayed launches. Withdrawn products. Re-filed submissions. Price corridors that no longer hold.
Three forces are responsible. None of them is new. What is new is their simultaneity — and the compounding effect when all three operate at once.
Force one: JCA has standardised the evidence bar
The EU Joint Clinical Assessment, which entered Cohort 1 scope in January 2025, has changed the nature of the European access problem. Before JCA, a company could design its evidence package to the requirements of its lead market — typically Germany or France — and manage other markets as secondary adaptations. JCA removes that option. A single comparative effectiveness assessment, conducted by a Joint Clinical Assessment Body drawing on multiple member states, sets the evidence standard for the entire assessment. There is no longer a "lead market" evidence package — there is one package, assessed once, with results that travel.
"JCA doesn't just raise the evidence bar. It removes the ability to manage that bar market by market. The whole architecture of evidence strategy has changed."
The implication is not simply that you need stronger evidence. It is that the design choices made in Phase 2 — PICO architecture, comparator selection, endpoint selection, trial population — are now JCA decisions as much as they are clinical decisions. Most companies running Phase 2 trials today are making evidence strategy decisions without a JCA lens. The submissions that result will reflect that.
Force two: MFN has linked European prices to US commercial outcomes
The three active MFN mechanisms — GENEROUS (voluntary, Medicaid), GLOBE (mandatory, Medicare Part B), and GUARD (mandatory, Medicare Part D) — have created a formal linkage between the price accepted in European markets and the ceiling available for US Medicare negotiation. The price accepted in Germany today is not just a German commercial decision. It is an input into the reference basket from which GLOBE and GUARD will draw.
MFN Mechanism Exposure by Asset Type
The sequencing implication is direct: the European market you launch in first — and at what price — is now a US strategic decision. Teams that are optimising European launch sequence for European access outcomes alone are solving the wrong problem.
Force three: Payer sophistication has outpaced industry adaptation
European payers have changed. The evidence standard they expect — comparative effectiveness against active comparators, patient-relevant endpoints, subgroup analyses that reflect their population — has risen consistently over the past five years. The proportion of submissions that are rejected, deferred, or accepted at deeply discounted prices because they fail to meet this standard has risen with it.
This is not a regulatory change. It is a market change. Payers have become more sophisticated faster than most access teams have adapted. The submissions being filed today were designed using mental models of payer expectations that are, in many cases, five years out of date.
What the old playbook assumed — and why those assumptions no longer hold
Three assumptions the old model depended on
National HTA systems are independent — no longer true under JCA. European pricing and US pricing are separate commercial decisions — no longer true under MFN. Access strategy is a pre-launch function — no longer true when the evidence decisions that determine access outcomes are made in Phase 2. All three assumptions underpinned the old playbook. All three have been invalidated simultaneously.
The decisions that still have leverage
The organisations that will navigate this environment well are those that recognise where decision leverage still exists — and act on it before the window closes. For most assets, that window is Phase 2.
- Is your Phase 2 trial designed to the JCA comparative effectiveness standard — or to the national HTA standard of your intended lead market?
- Has your European launch sequence been modelled against MFN reference basket exposure — or optimised purely for European access outcomes?
- Does your access function have a seat in Phase 2 trial design discussions — or does it inherit a trial that was optimised for regulatory approval?
- Are your US and EU commercial teams aligned on the price corridor implications of your European negotiating position?
The EU access playbook is not failing because companies are making bad access decisions. It is failing because the playbook was written for a different environment — and the environment changed faster than the planning assumptions did. The organisations that recognise this early enough to rebuild their approach around the new architecture will be in a structurally different position at launch. The ones that don't will find out the hard way that the old playbook has stopped working.